Adenocarcinoma is the predominant histological subtype of lung cancer, the leading cause of cancer deaths in the world. At stage I, the tumor is cured by surgery alone in about 60% of cases. Markers are needed to stratify patients by prognostic outcomes and may help in devising more effective therapies for poor prognosis patients. To achieve this goal, we used an integrated strategy combining meta-analysis of published lung cancer microarray data with expression profiling from an experimental model. The resulting 80-gene model was tested on an independent cohort of patients using RT-PCR, resulting in a 10-gene predictive model that exhibited a prognostic accuracy of approximately 75% in stage I lung adenocarcinoma when tested on 2 additional independent cohorts. Thus, we have identified a predictive signature of limited size that can be analyzed by RT-PCR, a technology that is easy to implement in clinical laboratories.
Fabrizio Bianchi, Paolo Nuciforo, Manuela Vecchi, Loris Bernard, Laura Tizzoni, Antonio Marchetti, Fiamma Buttitta, Lara Felicioni, Francesco Nicassio, Pier Paolo Di Fiore
Strategy of the study.
Validation of models as good predictors of prognosis in the Duke and IFOM validation cohorts is indicated. For details, see Results and Methods.